Company profile
Vogenx, Inc.
NASDAQ:VOGXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MIZAGLIFLOZIN | phase2 | — | 3 | completed, not_yet_recruiting |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05721729 | phase2 | completed | 2023-06-23 | 2024-05-01 | Vogenx, Inc. | Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions |
| NCT07760961 | phase2 | not_yet_recruiting | 2026-10-01 | 2027-10-01 | Vogenx, Inc. | Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia |
| NCT05541939 | phase2 | completed | 2022-09-13 | 2023-02-17 | Vogenx, Inc. | Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects |
FDA applications (0)
No records yet.